Renoprotective effects of edoxaban, a factor Xa inhibitor
نویسندگان
چکیده
منابع مشابه
Edoxaban (Savaysa): A Factor Xa Inhibitor.
INTRODUCTION Atrial fi brillation (AF), the most common cardiac arrhythmia, is encountered in clinical practice with ever-increasing frequency.1 Older data suggest that the lifetime risk of AF in men and women older than 40 years of age is approximately one in four.2 The prevalence of AF has most likely increased due to the aging of the “baby-boomers” (AF is overwhelmingly a disease of age) and...
متن کاملEdoxaban: an investigational factor xa inhibitor.
Edoxaban: an investigational factor Xa inhibitor.
متن کاملEdoxaban: a new oral direct factor xa inhibitor.
Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolic events (VTE). Factor Xa is an attractive target for anticoagulant treatment, as it is the primary and rate-limiting source of amplification in th...
متن کاملPharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.
This study determined the mass balance and pharmacokinetics of edoxaban in humans after oral administration of [¹⁴C]edoxaban. After oral administration of 60 mg (as active moiety) of [¹⁴C]edoxaban to six healthy male subjects, serial blood/plasma and urinary and fecal samples were collected for up to 168 h postdose. All samples were analyzed for total radioactivity by liquid scintillation count...
متن کاملSafety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation.
Edoxaban is an oral, reversible, direct factor Xa inhibitor in phase III clinical development for the prevention of stroke in atrial fibrillation (AF). A phase II study was undertaken to evaluate the safety and efficacy of edoxaban in Asian patients with non-valvular AF with CHADS2 score ≥1. In a multicentre, active-controlled, double-blind edoxaban and open-label warfarin, parallel-group study...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Proceedings for Annual Meeting of The Japanese Pharmacological Society
سال: 2018
ISSN: 2435-4953
DOI: 10.1254/jpssuppl.wcp2018.0_po2-4-7